POELLATH advises EQT and Aldevron on sale of Aldevron Freiburg GmbH
The new business will operate under the name GENOVAC, the original name of the German company purchased by Aldevron in 2004.
GENOVAC is a leading antibody discovery and development company providing contract research and development services, including gene to recombinant antibody discovery and production one-stop shop programming. GENOVAC’s antibody discovery capabilities include genetic immunization, advanced hybridoma and multiple single B cell platforms. GENOVAC is headquartered in Fargo, N.D., and has an antibody discovery and production facility in Freiburg, Germany.
Private equity investor EQT acquired a majority stake in Aldevron in July 2019 through its EQT VIII Fund.
POELLATH advised EQT/Aldevron with the following team:
- Jens Hörmann (partner, M&A, private equity, Munich)
- Daniel Wiedmann (associated partner, anti-trust law, Frankfurt)
- Alexander Pfefferler (senior associate, M&A, private equity, Munich)
- Dr. Lena Hummel (associate, M&A, private Equity, Munich)
POELLATH advises EQT on its corporate transactions and investments on a regular basis.
Contact
